Strive Pharmaceuticals Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Strive Pharmaceuticals Pharmaceutical Import Records from India — 4 Products, $2.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Strive Pharmaceuticals — Pharmaceutical Importer Profile (2026) | 4 Products, $2.4M Trade | TransData Nexus

Strive Pharmaceuticals

Pharmaceutical Importer · United States · Antihistamines & Allergy Focus · $2.4M Total Trade · DGFT Verified

Strive Pharmaceuticals is a pharmaceutical importer based in United States with a total trade value of $2.4M across 4 products in 3 therapeutic categories. Based on 116 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Strive Pharmaceuticals sources from 3 verified Indian suppliers, with Truecare Biomedix accounting for 73.1% of imports.

Strive Pharmaceuticals — Import Portfolio & Supplier Network

Strive Pharmaceuticals import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Strive Pharmaceuticals?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Truecare Biomedix	$2.0M	131	73.1%
True Care Biomedix	$437.9K	15	15.7%
Elysium Pharmaceuticals Limited

What Formulations Does Strive Pharmaceuticals Import?

Formulation	Value	Ships
Cetaminophen & diphenhydramine hcl tablet 500/25MG (other details as per invoice	$140.6K	6
Acetaminophen & diphenhydramine hcl tablet 500/25MG (other details as per invoice)	$137.5K	3
Acetaminophen 250MG, aspirin 250MG & caffeine 65MG tablets USP (other details asper invoice	$131.8K	6
Diphenhydramine hydrochloride capsule	$125.5K	6
Diphenhydramine hydrochloride tablets blue 25MG	$118.3K	3
Diphenhydramine hydrochloride tablets	$104.7K	3
Acetaminophen 250MG, aspirin 250MG &	$100.0K	2
Acetaminophen & diphenhydramine hcl	$100.0K	2
Acetaminophen 250MG, aspirin 250MG & caffeine 65MG tablets USP Each film coatedtablet contains as per	$87.9K	3
Diphenhydramine hydrochloride tablets pink 25MG	$69.4K	3
Diphenhydramine hydrochloride capsule USP 25MG	$60.5K	4
Diphenhydramine hydrochloride tablets pink 25MG, o/d as per inv & pl.	$54.8K	3
Acetaminophen 250MG, aspirin 250MG & caffeine 65MG tablets USP, other details asper invoice & pl.	$53.7K	2
Diphenhydramine hydrochloride tablets	$50.0K	1
Acetaminophen & diphenhydramine hcl tablet 500/25MG	$50.0K	1

Strive Pharmaceuticals imports 83 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diphenhydramine	Antihistamines & Allergy	$1.4M	72	4.5%	6
2	Aspirin	Analgesics & Antipyretics	$739.4K	26	2.0%	8
3	Docusate	Gastrointestinal	$141.3K	8	1.5%	9
4	Bisacodyl	Gastrointestinal	$96.5K	10	1.1%	13

Strive Pharmaceuticals imports 4 pharmaceutical products across 3 categories into United States totaling $2.4M.

Strive Pharmaceuticals — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Strive Pharmaceuticals Inc. is a privately held pharmaceutical packaging and private-label solutions company headquartered in East Brunswick, New Jersey. Established in 2015, the company specializes in delivering high-quality over-the-counter (OTC) health and wellness products, including pain relief, stomach relief, sleep aids, cold and flu remedies, allergy treatments, topical care, and dietary supplements.

The company offers comprehensive services encompassing product development, regulatory documentation, packaging design, and retail compliance. With a state-of-the-art cGMP-certified facility, Strive Pharmaceuticals ensures that all products meet stringent FDA and industry standards. Their operations are supported by multiple distribution centers, enabling efficient supply to major retailers and national e-commerce partners across the United States.

2Distribution Network

Strive Pharmaceuticals operates from its headquarters in East Brunswick, New Jersey, and maintains multiple distribution centers to facilitate efficient supply across the United States. While specific warehouse locations are not publicly disclosed, the company's extensive distribution network ensures timely delivery to major retailers and national e-commerce partners nationwide.

3Industry Role

In the United States pharmaceutical supply chain, Strive Pharmaceuticals functions primarily as a pharmaceutical packaging and private-label solutions provider. By offering turnkey services that include product development, regulatory documentation, packaging design, and retail compliance, the company plays a crucial role in bringing OTC health and wellness products to market. Their focus on quality, compliance, and innovation positions them as a key intermediary between manufacturers and retailers.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Strive Pharmaceuticals

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Strive Pharmaceuticals imports finished pharmaceutical formulations from three verified Indian suppliers: TRUECARE BIOMEDIX, TRUE CARE BIOMEDIX, and ELYSIUM PHARMACEUTICALS LIMITED. The majority of shipments (73.1%) are sourced from TRUECARE BIOMEDIX, indicating a significant reliance on this supplier. This concentration suggests a strategic choice to maintain consistent product quality and supply chain efficiency. However, the heavy dependence on a single supplier could pose risks related to supply chain disruptions or changes in supplier performance. Diversifying the supplier base may enhance resilience and mitigate potential risks.

2Supply Chain Resilience

The resilience of Strive Pharmaceuticals' Indian supply chain is influenced by its reliance on a limited number of suppliers. While TRUECARE BIOMEDIX accounts for the majority of shipments, the company sources from two additional suppliers, providing some level of diversification. The diversity of formulations imported—83 unique formulations—indicates a broad product range, which can help mitigate risks associated with supply chain disruptions. However, the concentration of shipments from a few suppliers may expose the company to potential vulnerabilities. Ensuring that all suppliers adhere to stringent regulatory standards and maintaining alternative sourcing options can enhance supply chain resilience.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations to ensure that imported drugs meet safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines requirements for drug approval, labeling, and manufacturing practices. For Indian generics to enter the U.S. market, they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug. This pathway ensures that generic drugs are therapeutically equivalent to their branded counterparts.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. Manufacturers and importers must register with the FDA and comply with Current Good Manufacturing Practice (cGMP) regulations. cGMP certification, such as EU GMP, WHO GMP, or PIC/S, is recognized by the FDA and facilitates the importation process. Additionally, wholesale distributors must obtain appropriate state licenses to operate legally. These licenses ensure that entities involved in the distribution chain adhere to regulatory standards, maintaining the integrity and safety of pharmaceutical products.

Strive Pharmaceuticals — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Strive Pharmaceuticals' focus on importing finished pharmaceutical formulations in the therapeutic areas of Antihistamines & Allergy, Analgesics & Antipyretics, and Gastrointestinal reflects a strategic alignment with prevalent consumer health concerns. The substantial import value of Diphenhydramine ($1.4M) and Aspirin ($739K) indicates strong market demand for these products. The company's portfolio concentration on these top five products suggests a targeted approach to meet consumer needs in these categories. This strategy enables Strive Pharmaceuticals to leverage economies of scale and establish a strong market presence in these therapeutic areas.

2Sourcing Profile

Strive Pharmaceuticals' sourcing strategy emphasizes importing finished pharmaceutical formulations from India, focusing on a limited number of suppliers. This approach allows for streamlined operations and consistent product quality. The company's preference for suppliers with cGMP certifications, such as EU GMP, WHO GMP, or PIC/S, aligns with FDA requirements and facilitates the importation process. By maintaining a focused supplier base, Strive Pharmaceuticals can ensure compliance with regulatory standards and effectively manage its product portfolio.

3Market Positioning

Seller's Guide — How to Become a Supplier to Strive Pharmaceuticals

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Strive Pharmaceuticals' sourcing network. The company's reliance on a limited number of suppliers suggests potential for diversification. Indian exporters can capitalize on this by offering competitive pricing, consistent quality, and adherence to international regulatory standards. Building strong relationships and demonstrating reliability can position new suppliers as viable partners for Strive Pharmaceuticals.

2Requirements & Qualifications

Indian exporters seeking to supply Strive Pharmaceuticals and the U.S. market must obtain cGMP certifications recognized by the FDA, such as EU GMP, WHO GMP, or PIC/S. Additionally, they must comply with FDA regulations, including the submission of an Abbreviated New Drug Application (ANDA) for generic products. Ensuring that products meet FDA labeling requirements and quality standards is essential for successful market entry.

3How to Approach

Frequently Asked Questions — Strive Pharmaceuticals

What products does Strive Pharmaceuticals import from India?

Strive Pharmaceuticals imports 4 pharmaceutical products across 3 categories. Top imports: Diphenhydramine ($1.4M), Aspirin ($739.4K), Docusate ($141.3K), Bisacodyl ($96.5K).

Who supplies pharmaceuticals to Strive Pharmaceuticals from India?

Strive Pharmaceuticals sources from 3 verified Indian suppliers. The primary supplier is Truecare Biomedix (73.1% of imports, $2.0M).

What is Strive Pharmaceuticals's total pharmaceutical import value?

Strive Pharmaceuticals's total pharmaceutical import value from India is $2.4M, based on 116 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Strive Pharmaceuticals focus on?

Strive Pharmaceuticals imports across 3 categories. The largest: Antihistamines & Allergy (59.7%), Analgesics & Antipyretics (30.5%), Gastrointestinal (9.8%).

Get Full Strive Pharmaceuticals Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.